The company is collaborating with Prof. Martin Gleave, professor at the department of urological sciences, University of British Columbia and director of the prostate centre at Vancouver General Hospital.
ATL1101 is a second generation antisense inhibitor of the insulin-like growth factor-I receptor (IGF-Ir), which is a high interest target in cancer drug development. Previous in-vitro studies have shown the compound to be active in human cancer cells, and mouse toxicology studies have been completed to add to the data package that is already in place on ATL1101.
Mark Diamond, CEO of Antisense Therapeutics, said: “This research collaboration in prostate cancer capitalizes on the significant amount of data we have built on ATL1101. We now have our lead drug ATL1102 for multiple sclerosis in Phase IIa trials and the same drug has also shown potential in the field of asthma. In addition, we have our growth and sight disorders drug ATL1103 progressing towards clinical development, and now we have ATL1101 entering preclinical research in prostate cancer.”